Financial Performance - Total fourth-quarter revenue for Intellicheck rose 12% year over year to $6.63 million, up from $5.93 million in the same period of 2024 [1] - SaaS revenue accounted for nearly all of fourth-quarter revenue and rose 12% to $6.62 million [1] - For full-year 2025, Intellicheck reported net income of $1.27 million, or $0.06 per diluted share, compared with a net loss of $918,000 in 2024 [2] - Adjusted earnings before interest, taxes, depreciation, and amortization improved to $2.57 million for the full year, up from $520,000 in the same period of 2024 [2] - As of Dec. 31, 2025, Intellicheck held $9.65 million in cash and $20.69 million in stockholders' equity [2] Operational Metrics - Gross margin remained at 91.4%, while operating expenses declined 7% to $4.57 million [1] - Bryan Lewis, CEO of Intellicheck, stated that the company reached operating profitability for the first time in its history with $1.3 million net income for the year [2] Market Performance - Intellicheck has a market capitalization of $96.98 million, with a 52-week high of $7.48 and a 52-week low of $2.17 [4] - Over the past 12 months, the small-cap stock has gained 88.24% [4] - The stock closed the regular session at $4.80, down 1.84%, and is currently trading at roughly 49.5% of its 52-week range [4]

Financial Data and Key Metrics Changes - For the full year 2025, net revenues were $175.1 million, representing a 217% year-over-year growth, with Q4 revenue at $57.6 million, consistent with pre-release estimates [8][16] - Cash operating expenses for Q4 were $50.3 million, better than the guidance of less than $55 million, and full-year cash operating expenses were approximately $284 million, at the low end of the range provided [9][18] - The company reported a loss from operations of approximately $320,000 for Q4, a 95% improvement compared to Q3 [17] Business Line Data and Key Metrics Changes - The sales organization is positioned to deliver growth, with over 1.1 million total prescriptions of VOQUEZNA filled to more than 230,000 patients, indicating strong market penetration [12] - In Q4, 273,000 prescriptions were filled, with 174,000 being covered prescriptions, representing a 21% quarter-over-quarter growth [12] Market Data and Key Metrics Changes - The company targets a market of approximately 65 million patients with gastroesophageal reflux, of which 40% experience inadequate symptom relief from PPIs [12] - The gross margin remained consistent at approximately 87% for both Q4 and the full year [17] Company Strategy and Development Direction - The company aims to achieve operating profitability beginning in Q3 2026 and cash flow positivity in 2027, with a revenue guidance of $320 million-$345 million for 2026 [7][24] - The focus is on enhancing the capital structure, reducing interest expenses, and executing a GI-focused strategy to drive growth [6][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2026, citing strong momentum and a nearly full-strength sales organization [14][15] - The company is not anticipating a fundamental change in broad Medicare coverage but is seeing incremental increases in Medicare prescriptions being covered [52] Other Important Information - The company successfully modified its term loan agreement, extending the maturity date to February 2029 and reducing the interest rate from 12% to 9.85% [19] - The company is exploring potential partnerships and additional products to expand its GI pipeline, although currently focusing on VOQUEZNA and its existing strategy [81][83] Q&A Session Summary Question: Early signals from the strengthened sales force and strategy - Management noted consistent signs of momentum, with a high percentage of gastroenterologists already writing prescriptions for VOQUEZNA and efforts focused on increasing writing frequency [31][32] Question: Dynamics of patients transitioning back to primary care - Management acknowledged an uplift in primary care prescribing volume but emphasized the current focus on gastroenterology [39] Question: Q1 sequential growth expectations - Management indicated typical seasonality effects and acknowledged that Q1 is generally the slowest quarter, but underlying metrics provide confidence for the full year [46][50] Question: Proportions of prescriptions filled through BlinkRx and GoodRx - Management reported that over half of prescriptions are routed through BlinkRx, with a small percentage utilizing GoodRx since its launch in November [60][65] Question: Long-term vision beyond VOQUEZNA - Management is actively considering additional products for the GI pipeline but is currently focused on executing the strategy for VOQUEZNA [80][83]

Core Insights - Wayfair reported a 6.9% year-on-year increase in total net revenue for Q4 2025, reaching $3.33 billion, and returned to operating profitability despite a slight decline in active customers [1][5] - The company achieved a full-year net revenue growth of 5.1% to $12.45 billion, with a notable improvement in operating income compared to the previous year [4][5] Financial Performance - Gross profit for Q4 2025 was $1.01 billion, representing 30.3% of net revenue, with operating income of $84 million, a significant turnaround from an operating loss of $117 million in the same quarter last year [2][4] - The net loss for Q4 narrowed to $116 million from $128 million year-on-year, while net cash from operating activities totaled $202 million [2][4] Customer Metrics - Active customers decreased by 0.5% year-on-year to 21.3 million, but last twelve months (LTM) net revenue per active customer increased by 5.6% to $586 [3] - Orders delivered rose by 3.7% to 11.1 million, with repeat customers accounting for 79.1% of orders and the average order value increasing to $301 from $290 [3] Strategic Insights - The results indicate revenue growth across both US and international segments, with the CEO highlighting a return to growth driven by organic business strategies [5][6] - The company emphasized its ability to capture market share despite macroeconomic challenges, leading to improved profitability [6]